

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-26. (Canceled)

27. (Withdrawn) A method for treating cancer, said method comprising administering to a subject in need thereof an effective amount of 4-1BB ligand or a fragment, derivative or analog thereof that activates 4-1BB and an effective amount of a nucleic acid molecule comprising a nucleotide sequence encoding a cytokine that activates the IL-15 receptor or IL-18 receptor.

28-37. (Canceled)

38. (Previously presented) A method for treating cancer, said method comprising administering to a subject in need thereof an effective amount of a nucleic acid molecule comprising a nucleotide sequence encoding IL-12 and an effective amount of 4-1BB ligand.

39-41. (Canceled)

42. (Previously presented) The method of claim 38, wherein the nucleotide sequence encoding IL-12 is regulated by a constitutive, inducible or tissue-specific promoter.

43-45. (Canceled)

46. (Currently amended) The method of claim 42 ~~or 45~~, wherein the nucleic acid molecule is contained in an expression vector.

47. (Canceled)

48. (Currently amended) The method of claim 42 ~~or 45~~, wherein the nucleic acid molecule is contained in a viral vector.

49. (Canceled)

50. (Previously presented) The method of claim 48, wherein the viral vector is an adenovirus vector.

51. (Canceled)

52. (Previously presented) The method of claim 48, wherein the viral vector is a retroviral vector or an adeno-associated viral vector.

53. (Canceled)

54. (Currently amended) The method of claim 38 ~~or 40~~, wherein the nucleotide sequence encodes human IL-12.
55. (Canceled)
56. (Currently amended) The method of claim 38 ~~or 39~~, wherein the 4-1BB ligand is human 4-1BB ligand.
57. (Canceled)
58. (Previously presented) The method claim 38, wherein the subject is a non-human mammal.
59. (Canceled)
60. (Previously presented) The method of claim 38, wherein the subject is a human.
61. (Canceled)
62. (Previously presented) The method of claim 38, wherein the cancer is a melanoma, neoplasm, tumor or metastasis.
63. (Canceled)
64. (Currently amended) The method of claim 38, wherein the cancer is colon cancer, colorectal cancer, melanoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, lung cancer or hepatic cancer.
65. (Canceled)
66. (Previously presented) The method of claim 38, wherein the nucleic acid molecule is administered intratumorally.
67. (Canceled)
68. (Previously presented) The method of claim 38, wherein the nucleic acid molecule is administered intradermally, intramuscularly, subcutaneously, intraperitoneally, intravenously or orally.
69. (Canceled)
70. (Currently amended) The method of claim 38 ~~or 39~~, wherein the 4-1BB ligand is administered intratumorally, intradermally, intramuscularly, subcutaneously, intraperitoneally, intravenously or orally.
71. (Canceled)

72. (New) The method of claim 38, wherein said nucleic acid molecule is introduced into a cell prior to administration of said cell to said subject.

73. (New) The method of claim 46, 48, 50, or 52, wherein said nucleic acid molecule is introduced into a cell prior to administration of said cell to said subject.

74. (New) The method of claim 72, wherein said cell is a fibroblast, monocyte, or progenitor cell obtained from bone marrow.

75. (New) The method of claim 73, wherein said cell is a fibroblast, monocyte, or progenitor cell obtained from bone marrow.